1095 related articles for article (PubMed ID: 24550439)
1. Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2.
Natsuaki M; Morimoto T; Furukawa Y; Nakagawa Y; Kadota K; Yamaji K; Ando K; Shizuta S; Shiomi H; Tada T; Tazaki J; Kato Y; Hayano M; Abe M; Tamura T; Shirotani M; Miki S; Matsuda M; Takahashi M; Ishii K; Tanaka M; Aoyama T; Doi O; Hattori R; Kato M; Suwa S; Takizawa A; Takatsu Y; Shinoda E; Eizawa H; Takeda T; Lee JD; Inoko M; Ogawa H; Hamasaki S; Horie M; Nohara R; Kambara H; Fujiwara H; Mitsudo K; Nobuyoshi M; Kita T; Kimura T;
Circ Cardiovasc Interv; 2014 Apr; 7(2):168-79. PubMed ID: 24550439
[TBL] [Abstract][Full Text] [Related]
2. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
[TBL] [Abstract][Full Text] [Related]
3. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical outcomes after everolimus- and sirolimus-eluting coronary stent implantation: final 3-year follow-up of the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial.
Shiomi H; Kozuma K; Morimoto T; Igarashi K; Kadota K; Tanabe K; Morino Y; Akasaka T; Abe M; Suwa S; Muramatsu T; Kobayashi M; Dai K; Nakao K; Uematsu M; Tarutani Y; Fujii K; Simonton CA; Kimura T;
Circ Cardiovasc Interv; 2014 Jun; 7(3):343-54. PubMed ID: 24803436
[TBL] [Abstract][Full Text] [Related]
5. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: results of Korean multicenter angioplasty team (KOMATE) Registry.
Kim BK; Oh S; Jeon DW; Yang JY; Kim JS; Park S; Choi D; Jang Y; Hong BK; Kwon HM; Lee SW; Goh CW; Kwon K; Ryu SK;
J Interv Cardiol; 2009 Oct; 22(5):411-9. PubMed ID: 19702679
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
8. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial.
Kelbaek H; Kløvgaard L; Helqvist S; Lassen JF; Krusell LR; Engstrøm T; Bøtker HE; Jørgensen E; Saunamäki K; Aljabbari S; Thayssen P; Galløe A; Jensen GV; Thuesen L
J Am Coll Cardiol; 2008 May; 51(21):2011-6. PubMed ID: 18498953
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.
Jensen LO; Tilsted HH; Thayssen P; Kaltoft A; Maeng M; Lassen JF; Hansen KN; Madsen M; Ravkilde J; Johnsen SP; Sørensen HT; Thuesen L
EuroIntervention; 2010 Apr; 5(8):898-905. PubMed ID: 20542774
[TBL] [Abstract][Full Text] [Related]
11. Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study).
Van den Branden BJ; Rahel BM; Laarman GJ; Slagboom T; Kelder JC; Ten Berg JM; Suttorp MJ
EuroIntervention; 2012 Feb; 7(10):1189-96. PubMed ID: 22030323
[TBL] [Abstract][Full Text] [Related]
12. Long-term clinical follow-up after sirolimus-eluting stent versus bare metal stent implantation in patients with acute coronary syndrome.
Ogita M; Nakamura T; Fujiwara N; Sakakura K; Funayama H; Sugawara Y; Kubo N; Ako J; Momomura S
J Interv Cardiol; 2009 Jun; 22(3):216-21. PubMed ID: 19490360
[TBL] [Abstract][Full Text] [Related]
13. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.
Omar A; Torguson R; Kitabata H; Pendyala LK; Loh JP; Magalhaes MA; Satler LF; Suddath WO; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2014 Dec; 84(7):1053-60. PubMed ID: 24619969
[TBL] [Abstract][Full Text] [Related]
15. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial.
Violini R; Musto C; De Felice F; Nazzaro MS; Cifarelli A; Petitti T; Fiorilli R
J Am Coll Cardiol; 2010 Feb; 55(8):810-4. PubMed ID: 20170821
[TBL] [Abstract][Full Text] [Related]
17. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
18. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries.
Yoshida T; Sakata K; Nitta Y; Taguchi T; Kaku B; Katsuda S; Shimojima M; Gamou T; Nakahashi T; Konno T; Kawashiri MA; Yamagishi M; Hayashi K
Heart Vessels; 2016 May; 31(5):635-42. PubMed ID: 25758470
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
